

Disclosures

Personal Commercial (42)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Research/Research Grants	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
Amarin	Research/Research Grants ‡ <i>REDUCE-IT</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Amgen Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology Prevention</i>
Astra Zeneca	Research/Research Grants ‡ <i>SAVOR-TIMI 53; THEMIS</i>	Significant (>= \$5,000)	<i>General Cardiology Prevention</i>
Belvoir Publications	Other - <i>Editor, Harvard Heart Letter</i>	Significant (>= \$5,000)	<i>Noninvasive Imaging Invasive CV Angio and Interventions Prevention Heart Failure and Cardiomyopathies General Cardiology Vascular Medicine</i>
Bristol Myers Squibb	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology Invasive CV Angio and Interventions</i>
Cardax	Other	None (\$0)	<i>General Cardiology</i>
Cereno Scientific	Other - <i>Scientific Advisory Board</i>	None (\$0)	<i>General Cardiology</i>
Chiesi	Research/Research Grants ‡ <i>CHAMPION PHOENIX</i>	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
Clinical Cardiology	Other - <i>Deputy Editor</i>	None (\$0)	<i>Prevention Heart Failure and Cardiomyopathies Arrhythmias and Clinical EP Vascular Medicine Noninvasive Imaging Invasive CV Angio and Interventions General Cardiology Congenital Heart Disease and Pediatric Cardiology Cardiothoracic Surgery</i>
Eisai	Research/Research Grants	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions General Cardiology</i>
Eli Lilly and Company	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Elsevier	Other - <i>Royalty</i>	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>
Elsevier Practice Update Cardiology	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology Invasive CV Angio and Interventions</i>
Ethicon	Research/Research Grants ‡ <i>STAMPEDE</i>	Significant (>= \$5,000)	<i>Prevention General Cardiology</i>
FlowCo	Research/Research Grants	None (\$0)	<i>Invasive CV Angio and Interventions</i>
Forest Laboratories	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>

Fractyl	Research/Research Grants	None (\$0)	General Cardiology
HMP Global	Other - <i>Editor, Journal of Invasive Cardiology</i>	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions</i>
Idorsia	Research/Research Grants	Significant (\geq \$5,000)	<i>Acute Coronary Syndromes</i>
Ironwood	Research/Research Grants	Significant (\geq \$5,000)	<i>General Cardiology</i>
Ischemix	Research/Research Grants ‡ <i>CARIN Trial</i>	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions</i>
Journal of Invasive Cardiology	Other - <i>Editor</i>	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions Arrhythmias and Clinical EP Congenital Heart Disease and Pediatric Cardiology Vascular Medicine General Cardiology</i>
Medscape Cardiology	Other	None (\$0)	<i>General Cardiology</i>
Medtelligence/WebMD	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>General Cardiology Prevention</i>
Medtronic	Research/Research Grants ‡ <i>SYMPPLICITY HTN-3</i>	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions General Cardiology</i>
Merck & Co., Inc.	Other - <i>Planning committee for clinical study</i>	None (\$0)	<i>Acute Coronary Syndromes Prevention Vascular Medicine</i>
Novo Nordisk Inc.	Research/Research Grants	None (\$0)	<i>General Cardiology</i>
Pfizer Inc	Research/Research Grants	Significant (\geq \$5,000)	<i>General Cardiology</i>
PhaseBio	Other - <i>Scientific Advisory Board</i>	None (\$0)	<i>General Cardiology</i>
PhaseBio	Research/Research Grants	Significant (\geq \$5,000)	<i>General Cardiology</i>
PLx Pharma	Research/Research Grants	None (\$0)	<i>General Cardiology Invasive CV Angio and Interventions</i>
Regado Biosciences	Other	None (\$0)	<i>Invasive CV Angio and Interventions General Cardiology</i>
Regeneron	Research/Research Grants	Significant (\geq \$5,000)	<i>Acute Coronary Syndromes General Cardiology Prevention</i>
Roche	Research/Research Grants	Significant (\geq \$5,000)	<i>Prevention General Cardiology</i>
Sanofi Aventis	Research/Research Grants	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions General Cardiology</i>
Slack Publications/Cardiology Research Foundation	Other - <i>Editor, Cardiology Today's Intervention</i>	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions</i>
Synaptic	Research/Research Grants	Significant (\geq \$5,000)	<i>General Cardiology</i>
Takeda	Research/Research Grants	None (\$0)	<i>General Cardiology Invasive CV Angio and Interventions</i>
The Medicines Company	Research/Research Grants ‡ <i>CHAMPION Trials</i>	Significant (\geq \$5,000)	<i>General Cardiology Invasive CV Angio and Interventions</i>
TobeSoft	Officer, Director, Trustee, or other Fiduciary Role	Significant (\geq \$5,000)	<i>Other</i>
WebMD	Consultant Fees/Honoraria	Significant (\geq \$5,000)	<i>Invasive CV Angio and Interventions General Cardiology</i>

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American College of Cardiology	Other - Vice Chair, Accreditation Committee	Significant (>= \$5,000)	General Cardiology
American College of Cardiology	Other - Chair, ACTION Registry Steering Committee	None (\$0)	Acute Coronary Syndromes
American College of Cardiology	Other - Board of Trustees	None (\$0)	General Cardiology
American College of Cardiology	Other - Guest Editor, Associate Editor, JACC	Significant (>= \$5,000)	General Cardiology Invasive CV Angio and Interventions
American College of Cardiology	Other - Senior Associate Editor, ACC.org	Significant (>= \$5,000)	General Cardiology
American Heart Association	Other - Chair, American Heart Association Quality Oversight Committee	None (\$0)	General Cardiology
Baim Institute for Clinical Research † CSL Behring	Other - Clinical Trial Executive Committee Member	Significant (>= \$5,000)	Acute Coronary Syndromes
Cleveland Clinic † Edwards	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
Duke Clinical Research Institute † Ferring Pharmaceuticals	Other - Steering committee	Significant (>= \$5,000)	General Cardiology
Duke Clinical Research Institute † Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	Invasive CV Angio and Interventions General Cardiology
Duke Clinical Research Institute	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology Invasive CV Angio and Interventions
Duke Clinical Research Institute † Bristol-Myers Squibb/Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology Invasive CV Angio and Interventions
Duke Clinical Research Institute † Eli Lilly	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology Invasive CV Angio and Interventions
Harvard Clinical Research Institute † Boehringer Ingelheim	Other - Clinical Trial Executive Committee Member	Modest (< \$5,000)	Invasive CV Angio and Interventions General Cardiology
Harvard Clinical Research Institute † St. Jude	Data Safety Monitoring Board	Modest (< \$5,000)	Invasive CV Angio and Interventions
Mayo Clinic	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology Invasive CV Angio and Interventions
Mount Sinai Medical Center	Data Safety Monitoring Board	Modest (< \$5,000)	Invasive CV Angio and Interventions
Population Health Research Institute	Data Safety Monitoring Board	Modest (< \$5,000)	Invasive CV Angio and Interventions General Cardiology
Population Health Research Institute † Bayer Healthcare Pharmaceuticals	Other - COMPASS Steering Committee, Operations Committee, National Leader	Significant (>= \$5,000)	General Cardiology
Society of Chest Pain Centers	Other - Board of Directors, Secretary/Treasurer	Significant (>= \$5,000)	Arrhythmias and Clinical EP Heart Failure and Cardiomyopathies Invasive CV Angio and Interventions General Cardiology
VA Healthcare System	Other - VA CART Research and Publications Committee (Chair)	None (\$0)	Invasive CV Angio and Interventions

Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
BIOFLOW-V	Biotronik	Biotronik
EVOLVE Short DAPT Study	Boston Scientific	Boston Scientific

CardioMEMS HF System Post Approval Study

St. Jude Medical

St. Jude Medical

OPTIMIZE

Svelte

Svelte

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/22/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/22/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/23/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 5/24/2019

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.